Data-augmented machine learning redefines the effective concentration of eculizumab in complement blood disorders

2025-12-15 hematology Title + abstract only

Show abstract

Eculizumab, a humanized monoclonal antibody targeting the complement lytic pathway protein C5, has demonstrated high efficacy in the treatment of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder. However, recent reports have highlighted patients who exhibit a lack of treatment response, necessitating an increase in the recommended dose or a reduction in the dosing interval. In this study, we employe...

Data-augmented machine learning redefines the effective concentration of eculizumab in complement blood disorders

Predicted journal destinations